sur Onco-Innovations Limited (CVE:ONCO)
Onco-Innovations Pursues Strategic U.S. Growth Following Investor Spotlight
Onco-Innovations Limited has announced a strategic update focusing on their U.S. market expansion. This comes after CEO Thomas O'Shaughnessy's appearance on Cboe Canada's Investor Spotlight. The company aims to enhance cancer treatment technologies through innovation and AI-driven research.
Recent achievements include acquiring Inka Health AI, partnering with Dalton Pharma Services, and collaborating with the University of Alberta. Onco is preparing for a Phase 1 clinical trial in 2026, transitioning from preclinical research to clinical evaluation.
The company plans to cross-list on a U.S. stock exchange to expand investor access and strengthen ties with the North American research community. This strategy aims to boost shareholder value and support long-term growth.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Onco-Innovations Limited